TERT and cancer: In BRAFV600E-driven human cancer cells, including melanoma cell line A375, thyroid cancer cell lines BCPAP and 8305 C, and breast cancer cell line MDA-MB-231, MAPK/ERK signaling affects the binding capacity of GABP to mutant TERT promoter and eventually results in TERT activation.